"Bioassay Development and Automation"
|
08:00 |
08:30 |
Registration |
|
|
||
|
08:30 |
08:35 |
Welcome by the Chairman of ELRIG.de e.V. |
Tobias May |
Elrig.de e.V. |
||
|
08:35 |
09:05 |
Keynote presentation: Applying AI and Automation to Improve Drug Design |
Ola Engkvist |
AstraZeneca, Mölndal, S |
||
|
09:05 |
09:25 |
Activity is the key – Development of potency assays for biologics |
Wilhelm Alexander Mengel |
Abbvie, Ludwigshafen, D |
||
|
09:25 |
09:45 |
Large scale phenotypic screen on 3-D organotypic models of cancer’ |
Nil Ege |
ICR, London, UK |
||
|
09:45 |
10:05 |
Bi-specific Antibodies - A Platform Approach for Lead Generation and Screening in Final Format |
Georg Fertig |
Roche, Penzberg, D |
||
|
10:05 |
10:30 |
Coffee break & Poster session |
|
|
||
|
10:30 |
10:50 |
Cell Based Acoustic Liquid Handling: transfer from 96 to 384 well format |
Paula Urquhart |
Covance, Harrogate, UK |
||
|
10:50 |
11:10 |
Automation of Potency Assays: |
Hermann Beck |
Roche, Basel, CH |
||
|
11:10 |
11:30 |
Cell Based Assays and Automation - When details become obstacles |
Mario Graeve |
Fraunhofer IPA, Stuttgart, D |
||
|
11:30 |
11:50 |
Encoded Library Technologies as Integrated Lead Finding Platforms for Drug Discovery |
Johannes Ottl |
Novartis, Basel, CH |
||
|
11:50 |
12:10 |
Development of lead molecules for antibody therapies |
André Frenzel |
Yumab, Braunschweig, D |
||
|
12:10 |
13:50 |
Lunch Break & Poster Session |
|
|
||
|
13:50 |
14:10 |
From Sample to Result - Full-Automation of Potency Assays |
Katharina Künzel |
Boehringer Ingelheim, Biberach, D |
||
|
14:10 |
14:30 |
Anticalins: From concept molecules to clinical candidates |
Rachida Bel Aiba |
Pieris Pharmaceuticals, Freising, D |
||
|
14:30 |
14:50 |
Automation-enabled assay development for high throughput screening |
Nina Großmann |
Merck, Darmstadt, D |
||
|
14:50 |
15:10 |
Deep sequencing analysis of antibody phage display selection outputs: Leaving conventional screening behind |
Stefan Ewert |
Novartis, Basel, CH |
||
|
15:10 |
15:30 |
Bioactivity Assays & GMP |
Ulrike Herbrand |
Charles River, Erkrath, D |
||
|
15:30 |
15:50 |
Coffee break & Poster session |
|
|
||
|
15:50 |
16:10 |
Innovative Strategies for Antibody Lead Discovery and Optimization |
Ernst Weber |
Bayer, Leverkusen, D |
||
|
16:10 |
16:20 |
Snapshot: Turning Cells into Reagents – what makes a cell assay ready? |
Oliver Wehmeier |
Accellerate, Hamburg, D |
||
|
16:20 |
16:40 |
What does it take to Calculate Potency and which Data Do You Need?, |
Lasse StolzenbachWaehrens |
Novo Nordisk, Denmark |
||
|
16:40 |
16:50 |
Snapshot: Promega Bridging of ADCC Reporter Bioassay with improved PBMC-based ADCC Cytotoxicity Assay |
Axel Johann |
Promega, Mannheim, D |
||
|
16:50 |
17:00 |
High-throughput imaging-based micro-neutralization assays for vaccine evaluation and antiviral discovery
|
Martin Theiss |
Nexcelom, Manchester, UK |
||
|
17:00 |
|
Wrap up Forum 2020 |
|
|
||
